Tag Archives: Biotech

Science2Startup 2019: Bringing Venture & Academia Together
October 15, 2018

After last year’s inaugural success, we’re excited for 2019’s Science2Startup conference in April 2019, an invitation-only university-focused biotech entrepreneurship event aimed at building connectivity across the academic, tech transfer, and venture communities. Working with a steering committee comprised of Atlas,

Leave a comment

Report Card For 2017: My Crystal Ball Predictions For Biotech
December 22, 2017

Heading into the winter holidays always brings out festive reflections of the past year. Twelve months ago, we were thrilled to say goodbye to 2016 and excited to embrace 2017’s promise.  And in large part, the past year has delivered

Leave a comment

Specialist Fund Flows Help Fuel The Biotech Capital Markets
October 17, 2016

Fund flows between sectors are a critically important dynamic in the equity capital markets: when net fund flows are positive, more demand for equity exists and stock price movement bias upwards; conversely, when fund flows are negative, the selling pressure

Leave a comment

Biotech IPOs: Outliers, Value Creation, And The Dispersion Of Returns
September 27, 2016

Although many wrote off the biotech IPO markets as moribund earlier in 2016, the sector has been quietly issuing a steady stream of new offerings. Despite the volatility related to drug pricing, and disastrous first six-weeks of the year, we’ve

1 Comment

Life After The Street: Why Biotech Is Winning Over Wall Street Talent
July 5, 2016

This blog was written by Ron Renaud, CEO of RaNA Therapeutics, as part of the From The Trenches feature of LifeSciVC. About three weeks ago, I attended a dinner organized by a good friend and former sell-side competitor, Dr. Yaron

1 Comment

I/O: The Strategic Supernova In Cancer Today
June 22, 2016

With the big cancer confab ASCO 2016 fading into memory, R&D teams everywhere are getting back to work on their cancer programs – and across the industry many of them will be doing the same work, on the same targets,

3 Comments

Are We Poised for a Neuroscience Research Renaissance?  Maybe
February 9, 2016

This blog was written by Adam Rosenberg, CEO of Rodin Therapeutics, as part of the From The Trenches feature of LifeSciVC. After a long, challenging period for CNS R&D – marked by late-stage clinical failures, mass layoffs, and limited early-stage

3 Comments

Psychology and Physiology of the Biotech Markets Today
October 30, 2015

Imagine you were an investor version of Rip Van Winkle. You went to sleep in October 2012 and woke up today. You’d take a quick look at biotech and think we were in a raging bull market. A few thoughts

Leave a comment

Infusing Biotech With Young Blood
January 30, 2015

This blog was written by Michael Gladstone, Principal at Atlas Venture, as part of the “From the Trenches” feature of LifeSciVC. Youth is often well represented among entrepreneurs – except in biotech. William Osler, founder of Johns Hopkins University and the

20 Comments

Venture-Backed Biotech Today: Reflections On Exits, Funding, and Startup Formation
January 22, 2015

Biotech is definitely red-hot, and has been for the past eight quarters. Immuno-oncology, cancer metabolism, gene therapy, orphan diseases, NASH, autoimmune – there’s a broad range of disease settings that are capturing the excitement and imagination of investors today. With some

6 Comments

Company Culture: Continuation On A LifeSciVC Theme
December 11, 2014

This blog was written by Jeff Hatfield, CEO of Vitae Pharmaceuticals, as part of the “From the Trenches” feature of LifeSciVC. Over the past two weeks in LifeSciVC, I read with great interest and appreciation the blogs of two friends of

3 Comments

The Biotech Cross-Over Phenom: Biomarker Of Quality?
November 7, 2014

As one of big drivers behind the recent IPO window, cross-over investing into private biotech companies by both mutual fund and hedge fund investors has become increasingly commonplace over the past couple years.  As described at the BIO Investor meeting

Leave a comment

Acquisitions As The Silent Partner In Biotech Liquidity: IPO vs M&A Exit Paths
October 27, 2014

With the biotech IPO window still open for business, and valuations of the recent classes of 2013 and 2014 remaining robust, all eyes have been focused on this part of the value chain.  Significant mezzanine pre-IPO rounds are getting done

2 Comments

Should I Stay Or Should I Go? Big Pharma Execs Taking The Biotech Plunge
October 6, 2014

That’s the dilemma facing drug hunters as leadership roles in biotech become more and more attractive.  You may have noticed that more and more seasoned pharma executives are making the move from big pharma or big biotech to lead small

Leave a comment

Talent: The Biggest Issue In Biotech Boardrooms Today
September 25, 2014

As with everything in life, it’s always about the people.  Bet the jockey, not the horse.  Great entrepreneurs and C-level executives are very hard to come by in R&D-intensive biotech companies, and its probably one of the biggest bottlenecks in

9 Comments

Data Insight: The Return Distribution Of BioPharma VC Financings
August 11, 2014

Return distributions in venture capital across different sectors have been a frequent source of commentary, and new data from Correlation Ventures provides further substrate for that theme. I’ve highlighted data from Correlation Ventures (CV) in the past, looking at top

1 Comment

VC-Backed Biotech IPOs: Valuations And Virtuous Cycles
August 4, 2014

As everyone in biotech knows, the last eighteen months have been an unprecedented time in the public capital markets.   2014 is on track to become the best year ever for life science IPOs, topping both 2013 and 2000.  Last week

Leave a comment

Patients: Our Purpose, Our Partners
July 9, 2014

My first experience in this life sciences industry, many years ago, was working as a pharmacist in a small town in the midwest. My most valued memories from that time were the instances when I was able to engage directly

2 Comments

Growing Beyond The Startup Phase: Lessons learned
July 1, 2014

So your biotech startup’s graduated to a Series A financing and your investors believe there’s nothing but champagne and robust clinical data in your future. Some classic analogies are applicable here; you’ve found a way off the island, you’ve defeated

Leave a comment

Goldilocks & The Pace Of Biotech Startup Creation
June 11, 2014

How many new biotechs should the industry be starting per year?  It’s a perennially asked question, and obviously not one with an easy and straightforward answer. On the one hand, if you believe only transformational new ideas should get funding,

4 Comments

Talent Acquisition: Pharma Is The Lifeblood Of Biotech
May 19, 2014

Startup Biotechs need bigger drug companies for lots of things, including R&D collaborations, investments, non-dilutive funding, and eventual liquidity via M&A. The health of today’s ecosystem depends on biotech and pharma working together. But one of the most important and

4 Comments

Risk: A User’s Guide For Drug Developers
May 14, 2014

In my last post, I argued that the key to the success – and perhaps even the survival – of the biopharma industry is to excel at risk management. We are in an inherently risky business, where there are thousands of

9 Comments

Leveraging Nature’s Experiments: Mitigating Drug Discovery Risks Through Human Genetics
May 8, 2014

Extreme clinical phenotypes caused by rare genetic variations have been the basis of some of the most exciting drug targets in today’s pharmaceutical pipeline: PCSK9 in cholesterol, sclerostin in bone diseases, Nav1.7 for pain.  The rare gene signatures underlying these

4 Comments

Tradeoffs and Timing: IPO vs. M&A Decision Making in Biotech
April 2, 2014

In light of the continued interest in biotech IPOs by the capital markets, there’s probably not a venture-backed biotech boardroom that hasn’t been discussing the merits of going public. Whether warranted or not, taking a company public via an IPO

1 Comment

Encouraging Biotech Innovation
March 31, 2014

Let’s face it, biotech entrepreneurs are innovation junkies.  We desperately want to deploy the most novel technologies to solve difficult problems in medicine and deliver new, life changing medicines for patients who need our help.  Independent of additional factors that

Leave a comment

Transformational Late Stage Drugs Delivered Through Deal-Making
March 21, 2014

Today’s biopharma industry has a richer and more exciting late stage pipeline of compelling new therapeutics than its had in years, drawing lots of enthusiasm from analysts and investors.  Goldman Sachs (GS) recently published a report on the “10 drugs

5 Comments

The Rookie Year and the Biotech CEO
March 12, 2014

Five years ago I stepped into my first (and so far only) CEO role. It seems impossible that it was five years ago but I definitely still remember many moments from my rookie year as a CEO – both successes

3 Comments

Biotech IPO Returns: Great, Good, And Not So Good
February 10, 2014

The biotech IPO bonanza appears to be continuing into 2014, with over thirteen offerings already this year.  We’re just now completing the busiest two week period in biotech IPOs ever.  Another dozen or so companies appear likely to price IPOs

Leave a comment

Crowdfunding: Angels in Biotech, or Devil in the Details?
December 11, 2013

In the tech-dominated venture capital world, 2013 could be called the year of the crowd.  With the JOBS Act and the emergence of credible platforms like AngelList, crowdfunding has come into the mainstream in a meaningful way. Social media, software,

5 Comments

Correlation’s Fresh Look At Venture Capital Returns
November 18, 2013

The broad underperformance of the venture capital asset class during the past decade is widely discussed; there’s a frequently-cited assertion that U.S. venture returns trailed the overall public equity stock market in the 2000s. Few if any published analyses have

11 Comments

Science Being Studied: Replication, Publication, And Resource Allocation
November 8, 2013

Scientific reproducibility hit mainstream this month with a feature article and editorial in The Economist; they highlight issues around the failure to replicate peer-reviewed research, academic biases found in science, use of scarce resources in national science budgets, and even share a primer in statistics

4 Comments

Biotech IPOs: The Exit Challenge As Lockups Expire
October 31, 2013

Six months ago the biotech industry was on the verge of a sizzling season for IPOs, and since then, on average, we’ve seen one new biotech IPO per week.  Valuations of many of these offerings have been impressive, and this

2 Comments

What’s Behind The Booming Biotech IPO Market
September 23, 2013

Biotech is back with a vengeance in this IPO window.  After a decade drought, we’ve witnessed over 30 new biotech offerings this year and more than $2.5B raised – the best IPO market since 2000.  In fact, it’s already the

2 Comments

The People Side of Biotech Deal-Making
July 24, 2013

Getting deals done with Pharma is critical to the strategy of many Biotech companies.  Pharma deals often offer less dilutive funding to advance a program or portfolio, market validation enabling future traction, and potentially important liquidity for shareholders.  Given their

5 Comments

Favorable 1H2011 Biotech M&A Trends
August 11, 2011

Our friends at HBM Partners just published their quarterly Biotech/Pharma M&A report.  Its got some good nuggets of data in it about 1H2011. Although its hard to think about in the midst of the Great August Rollercoaster in the markets,

Leave a comment